Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1978 1
1979 4
1980 1
1981 5
1982 2
1983 1
1984 1
1985 1
1986 1
1987 5
1988 2
1989 5
1990 3
1991 2
1992 4
1993 2
1994 4
1995 7
1996 3
1997 7
1998 4
1999 2
2000 4
2001 2
2002 3
2003 3
2004 5
2005 5
2006 3
2007 2
2008 4
2009 8
2010 8
2011 5
2012 12
2013 10
2014 16
2015 18
2016 23
2017 15
2018 20
2019 16
2020 40
2021 44
2022 45
2023 41
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

387 results

Results by year

Filters applied: . Clear all
Page 1
Ketamine treatment for depression: a review.
Yavi M, Lee H, Henter ID, Park LT, Zarate CA Jr. Yavi M, et al. Discov Ment Health. 2022;2(1):9. doi: 10.1007/s44192-022-00012-3. Epub 2022 Apr 15. Discov Ment Health. 2022. PMID: 35509843 Free PMC article. Review.
This manuscript reviews the clinical evidence regarding single-dose intravenous (IV) administration of the novel glutamatergic modulator racemic (R,S)-ketamine (hereafter referred to as ketamine) as well as its S-enantiomer, intranasal esketamine, for …
This manuscript reviews the clinical evidence regarding single-dose intravenous (IV) administration of the novel glutamatergic modula …
Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer.
Parikh SV, Lopez D, Vande Voort JL, Rico J, Achtyes E, Coryell W, Goddard A, Goes F, Greden JF, Singh B, Kaplin A, Frye MA, Maixner D, Watson B, Drake K, Tarnal V, Riva-Posse P, Bobo WV, Bio-K Study Team. Parikh SV, et al. Psychopharmacol Bull. 2021 Jun 1;51(3):109-124. Psychopharmacol Bull. 2021. PMID: 34421148 Free PMC article. Review.
The efficacy of subanesthetic intravenous ketamine for treatment resistant depression (TRD) has spurred a growth of clinics nationwide that provide this service. ...Together, this review provides key considerations for developing a ketamine clinic for depr
The efficacy of subanesthetic intravenous ketamine for treatment resistant depression (TRD) has spurred a growth of clinics na …
Oral Ketamine for Depression: A Systematic Review.
Rosenblat JD, Carvalho AF, Li M, Lee Y, Subramanieapillai M, McIntyre RS. Rosenblat JD, et al. J Clin Psychiatry. 2019 Apr 16;80(3):18r12475. doi: 10.4088/JCP.18r12475. J Clin Psychiatry. 2019. PMID: 30995364
OBJECTIVE: Intravenous (IV) ketamine has rapid and robust antidepressant effects; however, poor accessibility of the IV route often limits its use. ...CONCLUSIONS: A small number of clinical studies assessed the antidepressant effects of oral ketamine. …
OBJECTIVE: Intravenous (IV) ketamine has rapid and robust antidepressant effects; however, poor accessibility of the IV
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Reseau Canadien Pour Les Traitements De L'humeur Et De L'anxiete (Canmat) Concernant L'utilisation De La Ketamine Racemique Chez Les Adultes Souffrant De Trouble Depressif Majeur.
Swainson J, McGirr A, Blier P, Brietzke E, Richard-Devantoy S, Ravindran N, Blier J, Beaulieu S, Frey BN, Kennedy SH, McIntyre RS, Milev RV, Parikh SV, Schaffer A, Taylor VH, Tourjman V, van Ameringen M, Yatham LN, Ravindran AV, Lam RW. Swainson J, et al. Can J Psychiatry. 2021 Feb;66(2):113-125. doi: 10.1177/0706743720970860. Epub 2020 Nov 11. Can J Psychiatry. 2021. PMID: 33174760 Free PMC article.
OBJECTIVE: Patients with major depressive disorder often have limited response to first-line and second-line medications; hence, novel pharmacological treatments are needed for treatment-resistant depression (TRD). ...CONCLUSIONS: Single-dose IV racemi …
OBJECTIVE: Patients with major depressive disorder often have limited response to first-line and second-line medications; henc …
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Fava M, et al. Mol Psychiatry. 2020 Jul;25(7):1592-1603. doi: 10.1038/s41380-018-0256-5. Epub 2018 Oct 3. Mol Psychiatry. 2020. PMID: 30283029 Free PMC article.
We aimed to compare to active placebo the rapid acting antidepressant properties of a broad range of subanesthetic doses of IV ketamine among outpatients with treatment-resistant depression (TRD). ...Our results suggest that there is evidence for the efficacy …
We aimed to compare to active placebo the rapid acting antidepressant properties of a broad range of subanesthetic doses of IV ket
Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine.
Yao W, Cao Q, Luo S, He L, Yang C, Chen J, Qi Q, Hashimoto K, Zhang JC. Yao W, et al. Mol Psychiatry. 2022 Mar;27(3):1618-1629. doi: 10.1038/s41380-021-01377-7. Epub 2021 Nov 24. Mol Psychiatry. 2022. PMID: 34819637 Free PMC article.
(R,S)-ketamine elicits rapid-acting and sustained antidepressant actions in treatment-resistant patients with depression. ...Finally, single i.c.v. injection of CREB-HDO, BDNF exon IV-HDO or MCLs blocked the beneficial effects of (R)-ketamine on the re …
(R,S)-ketamine elicits rapid-acting and sustained antidepressant actions in treatment-resistant patients with depression. ...F …
Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.
Singh B, Kung S, Pazdernik V, Schak KM, Geske J, Schulte PJ, Frye MA, Vande Voort JL. Singh B, et al. J Clin Psychiatry. 2023 Feb 1;84(2):22m14548. doi: 10.4088/JCP.22m14548. J Clin Psychiatry. 2023. PMID: 36724113
There is a paucity of literature comparing subanesthetic intravenous (IV) ketamine and US Food and Drug Administration (FDA)-approved intranasal (IN) esketamine for TRD in real-world clinical settings. We compared the efficacy and time to achieve remission/re …
There is a paucity of literature comparing subanesthetic intravenous (IV) ketamine and US Food and Drug Administration (FDA)-a …
Ketamine for bipolar depression: an updated systematic review.
Fancy F, Haikazian S, Johnson DE, Chen-Li DCJ, Levinta A, Husain MI, Mansur RB, Rosenblat JD. Fancy F, et al. Ther Adv Psychopharmacol. 2023 Sep 26;13:20451253231202723. doi: 10.1177/20451253231202723. eCollection 2023. Ther Adv Psychopharmacol. 2023. PMID: 37771417 Free PMC article.
BACKGROUND: The therapeutic potential of subanesthetic doses of ketamine appears promising in unipolar depression; however, its effectiveness in treating bipolar depression (BD) remains uncertain. ...RESULTS: Eight studies were identified [pooled n = 235; mea …
BACKGROUND: The therapeutic potential of subanesthetic doses of ketamine appears promising in unipolar depression; however, it …
Oral ketamine for the treatment of pain and treatment-resistant depression.
Schoevers RA, Chaves TV, Balukova SM, aan het Rot M, Kortekaas R. Schoevers RA, et al. Br J Psychiatry. 2016 Feb;208(2):108-13. doi: 10.1192/bjp.bp.115.165498. Br J Psychiatry. 2016. PMID: 26834167 Review.
AIMS: To review the literature about the dosing regimen, duration, effects and side-effects of oral, intravenous, intranasal and subcutaneous routes of administration of ketamine for treatment-resistant depression and pain. METHOD: Searches in PubMed with the terms …
AIMS: To review the literature about the dosing regimen, duration, effects and side-effects of oral, intravenous, intranasal and subcutaneou …
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators.
Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, Zarate CA Jr, Deakin W, Abdallah CG, Feder A, Charney DS, Grunebaum MF, Mann JJ, Mathew SJ, Gallagher B, McLoughlin DM, Murrough JW, Muthukumaraswamy S, McMillan R, Sumner R, Papakostas G, Fava M, Hock R, Phillips JL, Blier P, Shiroma P, Šóš P, Su TP, Chen MH, Tiger M, Lundberg J, Wilkinson ST, Wallace ML. Price RB, et al. Mol Psychiatry. 2022 Dec;27(12):5096-5112. doi: 10.1038/s41380-022-01757-7. Epub 2022 Sep 7. Mol Psychiatry. 2022. PMID: 36071111 Free PMC article.
Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset antidepressant properties, but little is known regarding which patients are most likely to benefit, limiting personalized prescriptions. We identified randomized cont
Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset antidepressant properties,
387 results